BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38507971)

  • 21. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
    Salem JE; Allenbach Y; Vozy A; Brechot N; Johnson DB; Moslehi JJ; Kerneis M
    N Engl J Med; 2019 Jun; 380(24):2377-2379. PubMed ID: 31189043
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of abatacept in steroid refractory, immune checkpoint-induced myocarditis.
    Kalapurackal Mathai V; Black A; Lovibond S; Binny S; Lipton J; Moldovan C
    Intern Med J; 2021 Nov; 51(11):1971-1972. PubMed ID: 34796633
    [No Abstract]   [Full Text] [Related]  

  • 23. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
    Cham J; Ng D; Nicholson L
    J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
    Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
    Front Immunol; 2021; 12():803410. PubMed ID: 34938300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series.
    Longinow J; Zmaili M; Skoza W; Kondoleon N; Marquardt R; Calabrese C; Funchain P; Moudgil R
    Cancer Med; 2023 Feb; 12(3):2281-2289. PubMed ID: 36128926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
    Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
    Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac Troponins for Diagnosis and Prognostic Assessment of Immune Checkpoint Inhibitor Myocarditis and Myositis: The Emerging Importance of Peripheral Vision.
    deFilippi C; Barac A
    Circulation; 2023 Oct; 148(15):1135-1137. PubMed ID: 37812655
    [No Abstract]   [Full Text] [Related]  

  • 29. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
    Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
    Jespersen MS; Fanø S; Stenør C; Møller AK
    Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibitor-induced Myositis.
    Jayan A; Mammen AL; Suarez-Almazor ME
    Rheum Dis Clin North Am; 2024 May; 50(2):281-290. PubMed ID: 38670726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
    Puwanant A; Isfort M; Lacomis D; Živković SA
    Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ruxolitinib for Refractory PL-12 Antisynthetase Syndrome-Associated Angioedema-Like Panniculitis With Clonal T-Cell Receptor Gene Rearrangement.
    Sengupta S; Law B; Sennett R; Jedrych JJ; Albayda J; Kang JK
    JAMA Dermatol; 2024 Mar; 160(3):363-366. PubMed ID: 38117485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
    Fazal M; Prentice DA; Kho LK; Fysh E
    Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature.
    Cuenca JA; Hanmandlu A; Wegner R; Botdorf J; Tummala S; Iliescu CA; Nates JL; Reddy DR
    BMC Anesthesiol; 2023 Sep; 23(1):310. PubMed ID: 37700240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma.
    Sessums M; Yarrarapu S; Guru PK; Sanghavi DK
    BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33298477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
    Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitor-related myositis and myocarditis with multiple myositis-specific/-associated antibodies.
    Isa M; Hongo Y; Sakamoto N; Yamazaki K; Takazaki H; Asakuma J; Ikewaki K; Suzuki K
    J Neurol Sci; 2023 Jan; 444():120528. PubMed ID: 36565689
    [No Abstract]   [Full Text] [Related]  

  • 39. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
    Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
    Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.